Opiate Receptors and Antagonists: From Bench to Clinic

Front Matter....Pages i-xxiii
Ultra-Low-Dose Opioid Antagonists Enhance Opioid Analgesia and Reduce Tolerance....Pages 3-17
Upregulation of Opioid Receptors....Pages 19-44
Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders....Pages 45-65
Opioid Receptor Antagonist-Mediated Signaling in the Immune System....Pages 67-80
The Chemistry and Pharmacology of μ-Opioid Antagonists....Pages 83-97
Medicinal Chemistry of Kappa Opioid Receptor Antagonists....Pages 99-118
The Chemistry and Pharmacology of Delta Opioid Antagonists....Pages 119-136
Novel Opioid Antagonists with Mixed/Dual Selectivity....Pages 137-151
Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists....Pages 153-174
Methylnaltrexone: A Peripherally Acting Opioid Antagonist....Pages 175-198
Opioid Antagonist Effects in Animal Models Related to Opioid Abuse: Drug Discrimination and Drug Self-Administration....Pages 201-226
Naltrexone for Initiation and Maintenance of Opiate Abstinence....Pages 227-245
Ultra-Low-Dose Naltrexone Decreases Dependence and Addictive Properties of Opioids....Pages 247-261
Can a Combination Formulation Containing a Neutral Opiate Antagonist Decrease the Abuse of μ-Agonist Opiates....Pages 263-272
Effects of Opioid Antagonists on the Abuse-Related Effects of Psychomotor Stimulants and Nicotine....Pages 273-298
Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence....Pages 299-314
Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions....Pages 315-332
Opioid Antagonists and Ethanol\'s Ability to Reinforce Intake of Alcoholic Beverages: Preclinical Studies....Pages 335-369
Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence....Pages 371-386
Preclinical Effects of Opioid Antagonists on Feeding and Appetite....Pages 387-406
CNS Opiate Systems and Eating Disorders....Pages 407-421
Potential Utility of Kappa Ligands in the Treatment of Mood Disorders....Pages 425-444
Opioid Antagonists in the Treatment of Pathological Gambling and Kleptomania....Pages 445-456
Efficacy of Opioid Antagonists in Attentuating Self-Injurious Behavior....Pages 457-472
Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia....Pages 473-483
Current Issues in the Use of Opioid Antagonists (Naltrexone for Opiate Abuse: A Re-Educational Tool as Well as an Effective Drug)....Pages 487-510
Emergency Room Use of Opioid Antagonists in Drug Intoxication and Overdose....Pages 511-539
Kappa-Opioid Antagonists as Pruritogenic Agents....Pages 541-549
Clinical Effect of Opioid Antagonists on Clinical Pruritus....Pages 551-567
Effects of Opioid Antagonists on l -DOPA-Induced Dyskinesia in Parkinson\'s Disease....Pages 569-580
Endocrine Effects of Opioid Antagonists....Pages 581-604
Opioid Antagonists in Traumatic Shock: Animal and Human Studies....Pages 605-623
The Efficacy of Opioid Antagonists Against Heatstroke-Induced Ischemia and Injury in Rats....Pages 625-640
A Review of the Opioid System in Cancer Patients and Preliminary Results of Opioid Antagonists in the Treatment of Human Neoplasms....Pages 641-653
Nonclinical Pharmacology of VIVITROL ® : A Monthly Injectable Naltrexone for the Treatment of Alcohol Dependence....Pages 655-674
The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence....Pages 675-688
The Development of ProNeura Technology for the Treatment of Addictions....Pages 689-708
Development of Opioid Transdermal Delivery Systems....Pages 709-728
Intranasal Naloxone for Treatment of Opioid Overdose....Pages 729-739
Back Matter....Pages 741-757